Key Limitations and New Insights Into the Toxoplasma gondii Parasite Stage Switching for Future Vaccine Development in Human, Livestock, and Cats
Open Access
- 25 November 2020
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 10
Abstract
Toxoplasmosis is a parasitic disease affecting human, livestock and cat. Prophylactic strategies would be ideal to prevent infection. In a One Health vaccination approach, the objectives would be the prevention of congenital disease in both women and livestock, prevention/reduction ofT. gondiitissue cysts in food-producing animals; and oocyst shedding in cats. Over the last few years, an explosion of strategies for vaccine development, especially due to the development of genetic-engineering technologies has emerged. The field of vaccinology has been exploring safer vaccines by the generation of recombinant immunogenic proteins, naked DNA vaccines, and viral/bacterial recombinants vectors. These strategies based on single- or few antigens, are less efficacious than recombinant live-attenuated, mostly tachyzoiteT. gondiivaccine candidates. Reflections on the development of an anti-Toxoplasmavaccine must focus not only on the appropriate route of administration, capable of inducing efficient immune response, but also on the choice of the antigen (s) of interest and the associated delivery systems. To answer these questions, the choice of the animal model is essential. If mice helped in understanding the protection mechanisms, the data obtained cannot be directly transposed to humans, livestock and cats. Moreover, effectiveness vaccines should elicit strong and protective humoral and cellular immune responses at both local and systemic levels against the different stages of the parasite. Finally, challenge protocols should use the oral route, major natural route of infection, either by feeding tissue cysts or oocysts from differentT. gondiistrains. EffectiveToxoplasmavaccines depend on our understanding of the (1) protective host immune response duringT. gondiiinvasion and infection in the different hosts, (2) manipulation and modulation of host immune response to ensure survival of the parasites able to evade and subvert host immunity, (3) molecular mechanisms that define specific stage development. This review presents an overview of the key limitations for the development of an effective vaccine and highlights the contributions made by recent studies on the mechanisms behind stage switching to offer interesting perspectives for vaccine development.Keywords
Funding Information
- Université de Tours
This publication has 257 references indexed in Scilit:
- Recognition of Profilin by Toll-like Receptor 12 Is Critical for Host Resistance to Toxoplasma gondiiImmunity, 2013
- Toxoplasma gondii HLA-B*0702-restricted GRA720-28 peptide with adjuvants and a universal helper T cell epitope elicits CD8+ T cells producing interferon-γ and reduces parasite burden in HLA-B*0702 miceHuman Immunology, 2012
- The IRG protein-based resistance mechanism in mice and its relation to virulence in Toxoplasma gondiiCurrent Opinion in Microbiology, 2011
- CD8α+ Dendritic Cells Are the Critical Source of Interleukin-12 that Controls Acute Infection by Toxoplasma gondii TachyzoitesImmunity, 2011
- Towards an immunosense vaccine to prevent toxoplasmosis: Protective Toxoplasma gondii epitopes restricted by HLA-A*0201Vaccine, 2011
- Monocytes mediate mucosal immunity to Toxoplasma gondiiCurrent Opinion in Immunology, 2010
- Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humansVaccine, 2010
- Mic1-3 KnockoutToxoplasma gondiiis a good candidate for a vaccine againstT. gondii-induced abortion in sheepVeterinary Research, 2010
- Gut Commensal Bacteria Direct a Protective Immune Response against Toxoplasma gondiiCell Host & Microbe, 2009
- Toxoplasma co-opts host gene expression by injection of a polymorphic kinase homologueNature, 2006